B. D. Duisenbayev
B. D. Duisenbayev has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- A. M. Keramatdinova
LLP “OtarBioPharm
2 shared publications - N. B. Yessimbekova
LLP “OtarBioPharm
2 shared publications - Z. D. Ershebulov
Limited Liability Partnership “OtarBioPharm”, QazBioPharm National Holding JSC, Gvardeiskiy 080409, Kazakhstan
2 shared publications - A. M. Kurmantai
LLP “OtarBioPharm
1 shared publication - G. K. Sheriazdan
LLP “OtarBioPharm
1 shared publication - G.K. Kartbay1 shared publication
Latest Publications
- 10 April 2026
- Published by Research Institute for Biological Safety Problems in Biosafety and Biotechnology
- No. 24
MICROBIOLOGICAL MONITORING OF CLEANROOMS IN THE PRODUCTION OF STERILE PRODUCTS
The study presents the results of microbiological assessment of cleanrooms during the industrial production of foot-and-mouth disease vaccine under aseptic processing conditions. The investigations were conducted in Grade A and B areas during 2024–2025. More than 1,800 samples of air, equipment surfaces, and personnel gowning were analyzed. No microbial contamination was detected in air or on production surfaces. In 1.9% of samples taken from personnel garments and gloves, single microorganisms were identified within acceptable regulatory limits. The obtained data indicate the stability of aseptic conditions and the controlled state of the production environment.
- 10 April 2026
- Published by Research Institute for Biological Safety Problems in Biosafety and Biotechnology
- No. 24
MICROBIOLOGICAL MONITORING OF CLEANROOMS IN THE PRODUCTION OF STERILE PRODUCTS
The study presents the results of microbiological assessment of cleanrooms during the industrial production of foot-and-mouth disease vaccine under aseptic processing conditions. The investigations were conducted in Grade A and B areas during 2024–2025. More than 1,800 samples of air, equipment surfaces, and personnel gowning were analyzed. No microbial contamination was detected in air or on production surfaces. In 1.9% of samples taken from personnel garments and gloves, single microorganisms were identified within acceptable regulatory limits. The obtained data indicate the stability of aseptic conditions and the controlled state of the production environment.
- Open Access
- 27 March 2026
- Published by National Center for Biotechnology in Eurasian Journal of Applied Biotechnology
- No. 1,p. 42-51
OPTIMIZATION OF CULTIVATION CONDITIONS FOR RECOMBINANT INFLUENZA A/H5N1 STRAINS EXPRESSING BRUCELLA SPP. ANTIGENS (L7/L12, OMP16, OMP19, CU-ZN-SOD)
The study presents the results of optimizing cultivation conditions for recombinant influenza A/H5N1 strains (NS1-truncated) expressing Brucella spp. antigens (L7/L12, OMP16, OMP19, CU-ZN-SOD). MDCK and Vero cell lines were used in the experiments. The effects of the infectious dose, incubation temperature, cultivation duration, as well as the effect of protease on viral replication, were determined. It was found that the optimal conditions for cultivating recombinant influenza A strains expressing Brucella antigens are the use of MDCK cell culture, an infectious dose of 0.01 TCID50/cell, an incubation temperature of 34.0±0.5 °C, a cultivation period of 48 hours, and addition of Trypsin-TPCK at a concentration of 1.5–2.0 μg/mL. Under these conditions, viral infectivity reached ≥5.75 log TCID50/mL, and the hemagglutination titer was 1:32. The genetic stability of the viral constructs was maintained for at least four consecutive passages. The obtained results can be used in the development and scale-up of influenza vector vaccine production technology.
- 27 March 2026
- Published by National Center for Biotechnology in Eurasian Journal of Applied Biotechnology
- No. 1,p. 42-51
Open AccessOPTIMIZATION OF CULTIVATION CONDITIONS FOR RECOMBINANT INFLUENZA A/H5N1 STRAINS EXPRESSING BRUCELLA SPP. ANTIGENS (L7/L12, OMP16, OMP19, CU-ZN-SOD)
The study presents the results of optimizing cultivation conditions for recombinant influenza A/H5N1 strains (NS1-truncated) expressing Brucella spp. antigens (L7/L12, OMP16, OMP19, CU-ZN-SOD). MDCK and Vero cell lines were used in the experiments. The effects of the infectious dose, incubation temperature, cultivation duration, as well as the effect of protease on viral replication, were determined. It was found that the optimal conditions for cultivating recombinant influenza A strains expressing Brucella antigens are the use of MDCK cell culture, an infectious dose of 0.01 TCID50/cell, an incubation temperature of 34.0±0.5 °C, a cultivation period of 48 hours, and addition of Trypsin-TPCK at a concentration of 1.5–2.0 μg/mL. Under these conditions, viral infectivity reached ≥5.75 log TCID50/mL, and the hemagglutination titer was 1:32. The genetic stability of the viral constructs was maintained for at least four consecutive passages. The obtained results can be used in the development and scale-up of influenza vector vaccine production technology.